At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Ruxolitinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Exploratory Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus
In Brief
A Phase 2 clinical trial evaluating Ruxolitinib for Discoid Lupus Erythematosus. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the potential efficacy of topical ruxolitinib for the treatment of discoid lupus erythematosus (DLE)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiscoid Lupus Erythematosus
CountriesUnited States
CollaboratorsIncyte Corporation
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedJun 2021
Enrollment StartMay 2022
Primary CompletionMar 2024
TodayJul 2026
First PostedJun 1, 2021
Enrollment StartMay 4, 2022
Primary CompletionMar 4, 2024
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 5.1 years ago
Interventions
Ruxolitinibdrug
1.5% cream; Ruxolitinib cream will be applied topically twice daily to areas with active lesions.